FierceBiotech· @FierceBiotech · X·· 2 天前精选AI 评分65
AI 导读
Kodiak Sciences 的两款候选药物在一项 III 期临床试验中与 Eylea 达到相当结果，使该公司有望于今年为其眼科疾病资产之一寻求 FDA 批准。相关数据来自 Fierce Biotech 报道。
推荐理由
Kodiak 两款候选药在 III 期头对头中与 Eylea 打平，读者可据此判断其年内递交 FDA 上市申请的可能性。
正文
Two of Kodiak Sciences’ drug candidates have matched Eylea in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year. https://www.fiercebiotech.com/biotech/kodiak-roars-back-pivotal-victory-resurrected-eye-disease-drug
来源：FierceBiotech · x.com